Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New blood test could cut unnecessary transfusions in liver patients

NCT ID NCT07437755

Disease control Sponsor: Grigore T. Popa University of Medicine and Pharmacy Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study compares a new method using ROTEM (a rapid blood clotting test) to standard care for deciding whether to give blood products before high-risk procedures in patients with decompensated liver cirrhosis. The goal is to see if the ROTEM-guided approach reduces the number of patients receiving transfusions while keeping bleeding complications low. About 116 adults will be randomly assigned to either the ROTEM-guided strategy or usual care.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Blood products transfusion (platelets, fresh frozen plasma, cryoprecipitate) guided by ROTEM testing
What this could lead to
If successful, this could lead to fewer unnecessary blood transfusions and safer procedures for patients with liver cirrhosis.
What could go wrong
This is a small, single-center trial, so results may not apply broadly. The ROTEM-guided approach may not reduce bleeding or transfusions as hoped.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 116 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jun 2025

Expected to finish

Oct 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * diagnosed with decompensated liver cirrhosis of any etiology * planned for a high risk of bleeding invasive procedure * coagulopathic based on conventional coagulation tests and considered for pre-procedural blood component prophylaxis * able and willing to provide informed consent Exclusion Criteria: * acute liver failure * current use of anticoagulant treatment * patients on antiplatelet aggregation agents * patients who have received FFP, platelet transfusion, cryoprecipitate in the week prior to the procedure * patients with stage 4 or 5 chronic kidney disease or patients receiving renal replacement therapy * sepsis

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Decompensated liver cirrhosis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

chronic liver failure cirrhosis of liver

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Liver cirrhosis with acute decompensation

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Institute of Gastroenterology and Hepatology

    RECRUITING

    Iași, Iaşi, 700111, Romania

More trials for these conditions

Other studies related to the condition(s) this trial covers.